Collectively, these findings suggest that Sal B’s mechanism of action in NSCLC may involve the modulation of the miR-23a/PTEN/AKT signaling pathway, thereby highlighting its potential as a therapeutic candidate for NSCLC. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.